Not Signed In -
Gout |
Chondrocalcinisis; Gout and Pseudogout; Hyperuricemia; Pseudogout |
Clinical Trial: A Study Evaluating the Effect of of Etoricoxib and Indomethacin in the Treatment of Acute Gout.
This study is no longer recruiting patients.
|
Purpose
A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.
| Condition | Intervention | Phase |
|---|---|---|
| acute gout | Drug: MK0633; etoricoxib | Phase IV |
MedlinePlus related topics: Gout and Pseudogout
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 Mg Versus Indomethacin 150 Mg in the Treatment of Acute Gout
Further Study Details:
Study start: January 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Males or females at least 18 years of age who have acute gout.
Location Information
China
Merck Sharp & Dohme (China) Ltd., Beijing, 100738, China
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_062
Last Updated: September 9, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00142558
Health Authority: China: State Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 9, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00142558
Health Authority: China: State Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
